@tips_th1138:

King Tips
King Tips
Open In TikTok:
Region: US
Friday 28 August 2026 14:30:00 GMT
121070
245
6
4

Music

Download

Comments

rikkitikki353
richardbertrand47 :
wait,what
2026-08-29 02:48:25
0
roddyb165
RoddyB :
Why?
2026-08-28 23:45:27
0
chadantill
chadantill :
😳😳😳
2026-08-29 00:02:23
0
daddyrick59
DaddyRick59 :
🥰🥰🥰
2026-08-29 02:14:05
0
mikewhiteya
user1484422122818 :
😂😂😂
2026-08-29 07:38:27
0
To see more videos from user @tips_th1138, please go to the Tikwm homepage.

Other Videos

Big news in the world of Obesity Medicine and weight management today, and I want to make sure you actually understand what it means, not just that it happened. The FDA just approved Foundayo (orforglipron), Eli Lilly's once-daily GLP-1 pill for obesity, and it's worth paying attention to. Here's what you need to know: The clinical data: In the Phase 3 ATTAIN trials, patients lost an average of 12.4% of their body weight at the highest dose over 72 weeks. Real, meaningful weight loss. Less than Zepbound's ~21%, but this isn't a shot. It's a pill. The access piece: With commercial insurance, eligible patients could pay as little as $25/month. Self-pay starts at $149. Medicare Part D coverage could begin as early as July at $50/month. For a category where people have been paying $1,000+/month, that matters enormously. The practical difference: Unlike the Wegovy pill, which requires an empty stomach and a 30-minute wait, Foundayo can be taken any time, no food or water restrictions. Side effects: Same GI profile as the rest of this class. The thyroid cancer warning is there too, so if you have a history of medullary thyroid carcinoma, this isn't for you. Is it a replacement for the injectables? No. A legitimate option for people who want oral medication, or an oral maintenance strategy after hitting goal weight? Yes. I sat down one on one with Dave Ricks, CEO of Eli Lilly. That interview is coming, and I think it'll change how you think about where this whole category is headed. Stay close.   Note: I have not been compensated in any way for this post/interview.  #Foundayo #newGLP-1 #GLP-1pill #EliLilly
Big news in the world of Obesity Medicine and weight management today, and I want to make sure you actually understand what it means, not just that it happened. The FDA just approved Foundayo (orforglipron), Eli Lilly's once-daily GLP-1 pill for obesity, and it's worth paying attention to. Here's what you need to know: The clinical data: In the Phase 3 ATTAIN trials, patients lost an average of 12.4% of their body weight at the highest dose over 72 weeks. Real, meaningful weight loss. Less than Zepbound's ~21%, but this isn't a shot. It's a pill. The access piece: With commercial insurance, eligible patients could pay as little as $25/month. Self-pay starts at $149. Medicare Part D coverage could begin as early as July at $50/month. For a category where people have been paying $1,000+/month, that matters enormously. The practical difference: Unlike the Wegovy pill, which requires an empty stomach and a 30-minute wait, Foundayo can be taken any time, no food or water restrictions. Side effects: Same GI profile as the rest of this class. The thyroid cancer warning is there too, so if you have a history of medullary thyroid carcinoma, this isn't for you. Is it a replacement for the injectables? No. A legitimate option for people who want oral medication, or an oral maintenance strategy after hitting goal weight? Yes. I sat down one on one with Dave Ricks, CEO of Eli Lilly. That interview is coming, and I think it'll change how you think about where this whole category is headed. Stay close. Note: I have not been compensated in any way for this post/interview. #Foundayo #newGLP-1 #GLP-1pill #EliLilly

About